The objective of Quantum Genomics is to become a leading actor in the treatment of cardio-vascular diseases through the development of a new therapeutic class:
BAPAIs for BrainAminopeptidase A Inhibitors.
We wish to develop and provide effective and well tolerated therapeutic treatments for controlling high blood pressure and to for preventing related cardio-vascular risks such as heart failure.
High blood pressure remains a major public health concern.
Quantum Genomics is the only biopharmaceutical research company developing new therapies from a real breakthrough innovation based on the inhibition of brain Aminopeptidase A.
The mid-term strategic objective of the company is to sign partnership agreements with major pharmaceutical companies which will take over and bring the products from the BAPAI technology to the market.
Company Details
- Employees
- 4
- Founded
- -
- Address
- 33 Avenue Du Maine, Paris,75015,france
- Phone
- +33 1 85 34 77 70
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.quantum-genomics.com
- Keywords
- Hypertension and Heart Failure.
- HQ
- Paris
Quantum Genomics Questions
Quantum Genomics's helpline number is +33 1 85 34 77 70
Quantum Genomics's website is http://www.quantum-genomics.com
Quantum Genomics's LinkedIn profile is https://fr.linkedin.com/company/quantum-genomics
Quantum Genomics has
4 employees.
View email and phone details for 4
employees at Quantum Genomics.
Quantum Genomics's industry is
Pharmaceutical Manufacturing
Quantum Genomics's top competitors are
Hyppo,
Abivax,
Otium,
The Oasis House,
Néolithe,
Tilak Healthcare,
Whitelab Genomics,
Jimmy,
Exactcure,
Geneuro Sa.
Quantum Genomics's categories are Pharmaceutical Manufacturing
Quantum Genomics's founding year is 2006
